BioMarin Pharmaceutical (BMRN) Price Target Raised to $145 at RBC

Canaccord Genuity Raises Price Target on BioMarin Pharma (BMRN) Following BMN-111 Data

Canaccord Genuity reiterates a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $150.00 (from $115.00), following positive BMN-111 data. Analyst Adam Walsh increased the probability of success to 70%, from 50%, based on the strong P2 data.

Walsh commented, "We view the... More

BioMarin's (BMRN) Price Target Raised to $156 at Deutsche Bank

Deutsche Bank maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and raised its price target to $156.00 (from $140.00). The change follows positive phase 2 BMN-111 data in achondroplasia.

Analyst Robyn Karnauskas said, "BioMarins achondroplasia drug, BMN-111 (now called vosoritide) worked in phase 2, showing a 50% improvement in mean annualized growth velocity of... More

BioMarin Pharmaceutical (BMRN) PT Raised to $147 at Piper Jaffray Following Positive BMN-111 Update

Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and bumped his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $147.00 (from $123.00) following data from the long awaited P2 trial of BMN111 (vosoritide) in children with achondroplasia.

Schimmer commented, "Our... More

BioMarin (BMRN) PT Raised to $143 at Leerink Partners as BMN-111 Meets Primary Endpoint

Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and bumped his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $143.00 (from $136.00) reported positive top-line results for the BMN-111 (vosoritide) Ph II trial in Achondroplasia (ACH), meeting the primary endpoint with a 50% increase in annualized... More

BioMarin Pharma (BMRN) Issues Positive Update from BMN 111 Phase 2 Proof-of-Concept, Dose Finding Study

BioMarin Pharma (NASDAQ: BMRN) announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111 (vosoritide), an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia. Achondroplasia is the most common form of human dwarfism. Vosoritide has Orphan designation in both the United States and Europe.

Phase 2 Results and Safety Summary of First Six Months

Data from the 26 children participating in the Phase 2 study demonstrated a favorable safety profile and efficacy at the 15 micrograms/kilogram/daily dose. The 10 children in Cohort 3 treated with 15 micrograms per kilogram per... More